A prospective, randomized, double-blind, multicenter, placebo-controlled, parallel group, adaptive Phase 3 study with open-label extension to evaluate efficacy and safety of macitentan 75 mg in inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.

drug protocol number
67896062CTP3001
drug sponsor
Actelion Pharmaceuticals Ltd
drug study
Macitentan (ACT-064992, Opsumit ®)
drug trial site
King Fahad Medical City (Riyadh)
drug status
Completed
drug phase